American Society of Nephrology (ASN) 2022
Phase 3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Treatment of C3G or IC-MPGN
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.